SAINTE-FOY, QUEBEC -- (MARKET WIRE) -- November 21, 2006 -- Bioxel Pharma Inc. (TSX Venture Exchange: BIP), a leading manufacturer of taxane active pharmaceutical ingredients (APIs) and developer of targeted oncology drugs, is pleased to announce the filling of a second international patent application for the semi-synthesis of paclitaxel and docetaxel.
